abrdn Income Credit Strategies ACP Pharma — Total Costs & Expenses
Other financials
Where this comes from
Reported directly by abrdn Income Credit Strategies in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: abrdn Income Credit Strategies’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about abrdn Income Credit Strategies's pharma — total costs & expenses.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is abrdn Income Credit Strategies's pharma — total costs & expenses?
- abrdn Income Credit Strategies (ACP) reported pharma — total costs & expenses of $23M in Q1 2026.
- How has abrdn Income Credit Strategies's pharma — total costs & expenses changed year-over-year?
- abrdn Income Credit Strategies's pharma — total costs & expenses decreased by 11.5% year-over-year, from $26M to $23M.
- What is the long-term trend for abrdn Income Credit Strategies's pharma — total costs & expenses?
- Over 4 years (2021 to 2025), abrdn Income Credit Strategies's pharma — total costs & expenses has grown at a 5.5% compound annual growth rate (CAGR), from $88M to $109M.
- What does pharma — total costs & expenses mean?
- Represents the total aggregate expenditures incurred by the Pharma segment to support its operations, including cost of goods sold, research and development, and administrative overhead. This metric provides insight into the overall cost structure and operational efficiency of the business unit. Monitoring this helps investors assess the segment's ability to manage its expense base relative to revenue generation.